523 studies found for:    Open Studies | "Ovarian Diseases"
Show Display Options
Rank Status Study
21 Not yet recruiting Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
Condition: Ovarian Carcinoma
Interventions: Procedure: Radiofrequency ablation;   Biological: Cytokine-induced killer cells
22 Recruiting Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine
Interventions: Drug: Topotecan;   Drug: VX-970
23 Recruiting Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Solid Tumors
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: MEDI4736
24 Recruiting Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: veliparib;   Drug: carboplatin;   Drug: paclitaxel
25 Recruiting Prognosis and Long Term Pubertal Outcome of Girls Previously Diagnosed With a Prenatal Ovarian Cyst
Condition: Ovarian Cyst
Intervention: Other: Hormonal analysis, pelvic US
26 Recruiting Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Condition: Ovarian Cancer, TNBC, SqNSCLC, and Other Solid Tumours
Intervention: Drug: AZD 1775
27 Recruiting TIL Therapy for Metastatic Ovarian Cancer
Condition: Metastatic Ovarian Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL infusion;   Drug: Interleukin-2
28 Recruiting Venous Thromboembolic Complications in Ovarian Cancer
Conditions: Venous Thromboembolism;   Ovarian Neoplasms;   Ovarian Cancer;   Deep Vein Thrombosis;   Lung Embolism
Intervention:
29 Not yet recruiting Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention: Biological: GEN-1
30 Not yet recruiting DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
Conditions: Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Intervention:
31 Recruiting Platine, Avastin and OLAparib in 1st Line
Condition: Ovarian Cancer
Interventions: Drug: Olaparib;   Drug: Placebo
32 Recruiting Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI
Conditions: In Vitro Fertilization;   Polycystic Ovary Syndrome
Interventions: Drug: Long-acting Triptorelin;   Drug: Short-acting Triptorelin
33 Recruiting Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Condition: Epithelial Ovarian Cancer
Intervention: Device: Mirena® intra-uterine device (IUD)
34 Not yet recruiting To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer
Condition: BRCAm Ovarian Cancer
Intervention: Drug: Olaparib
35 Recruiting Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel
Conditions: Ovarian Cancer;   Endometrial Cancer;   Cervical Cancer;   Breast Cancer Triple Negative
Intervention: Drug: ARQ 092 + carboplatin + paclitaxel
36 Not yet recruiting A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis
Condition: Ovarian Cancer
Interventions: Drug: Cisplatin and doxorubicin;   Procedure: Cisplatin and doxorubicin
37 Recruiting Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasm
Interventions: Other: Placebo;   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel
38 Recruiting Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Conditions: Malignant Ovarian Clear Cell Tumor;   Malignant Ovarian Serous Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Biological: Aldesleukin;   Biological: HER2Bi-Armed Activated T Cells;   Other: Laboratory Biomarker Analysis;   Biological: Sargramostim
39 Not yet recruiting Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: Ketorolac;   Other: Placebo
40 Recruiting Women With Polycystic Ovary Syndrome (PCOS)
Condition: Polycystic Ovary Syndrome
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years